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Background: Cell signaling induced by pathogenic IgG in the human autoimmune skin disease pemphigus vulgaris con-
tributes to loss of adhesion.
Results: PV IgG activate EGFR downstream of p38 and inhibiting EGFR blocks antibody induced desmoglein endocytosis,
keratin retraction, and blistering.
Conclusion: PV IgG-mediated transactivation of EGFR contributes mechanistically to loss of keratinocyte cell-cell adhesion.
Significance: This study provides the mechanistic rationale for using EGFR inhibitors in PV.
The pemphigus family of autoimmune bullous disorders is
characterized by autoantibody binding to desmoglein 1 and/or 3
(dsg1/dsg3). In this study we show that EGF receptor (EGFR) is
activated following pemphigus vulgaris (PV) IgG treatment of
primary human keratinocytes and that EGFR activation is
downstream of p38 mitogen-activated protein kinase (p38).
Inhibition of EGFR blocked PV IgG-triggered dsg3 endocytosis,
keratin intermediate filament retraction, and loss of cell-cell
adhesion in vitro. Significantly, inhibiting EGFR prevented PV
IgG-induced blister formation in the passive transfer mouse
model of pemphigus. These data demonstrate cross-talk
between dsg3 and EGFR, that this cross-talk is regulated by p38,
and that EGFR is a potential therapeutic target for pemphigus.
Small-molecule inhibitors and monoclonal antibodies directed
against EGFR are currently used to treat several types of solid
tumors. This study provides the experimental rationale for
investigating the use of EGFR inhibitors in pemphigus.
Pemphigus is a group of human autoimmune blistering dis-
eases inwhich autoantibodies bind to desmosomal cadherins in
the skin and induce keratinocyte cell-cell detachment (e.g.
acantholysis). Pathogenic IgG binds to the ectodomain of des-
moglein (dsg)2 1 in pemphigus foliaceus (PF) (1, 2) and/or dsg3
in pemphigus vulgaris (PV) (3, 4). Accumulating evidence sug-
gests an essential role for intracellular signaling in the mecha-
nism by which pemphigus IgG induces acantholysis. A number
of intracellular signaling events have been observed when kera-
tinocytes are treated with pemphigus IgG (5–8). PV as well as
PF autoantibodies activate p38 MAPK in keratinocyte cultures
and in both the PV and PF passive transfer mouse models of
pemphigus (9–11). Pretreatment with p38 inhibitors blocked
PV and PF IgG-induced actin reorganization, keratin interme-
diate filament retraction (11, 12), dsg endocytosis (13), and blis-
tering in vivo (9, 10), suggesting a pivotal role for p38 signaling
in the mechanism of acantholysis. Unfortunately, clinical trials
of p38 inhibitors for pemphigus have been hindered by the hep-
atotoxicity of these compounds3.
Epidermal growth factor receptor (EGFR) is a prominent sig-
naling complex whose repertoire of functions is increased by
cross-communication with other signaling pathways (15). In
addition to its ligand-induced activity, EGFR can be transacti-
vated by various signaling pathways in a ligand-independent
manner (16–18). Activation of EGFR can lead to a variety of
biological outcomes including cell growth, migration, and sup-
pression of apoptosis. In the skin, EGFR signaling plays a major
role in regulating keratinocyte proliferation, and deregulation
of EGFR signaling has been observed in skin disorders such as
psoriasis, squamous cell carcinoma, and melanoma (19).
EGFR has been implicated in modulating cell adhesion junc-
tions, including desmosomes (20, 21). EGFR-regulated adhe-
sion plays an important role in modulating epithelial adhesion
and motility. For example, EGFR phosphorylation of -catenin
regulates adherens junction assembly/disassembly (22). An
increasing number of reports implicate a role for desmoglein-
EGFR interactions. Desmoglein 1 has been shown to suppress
EGFR-Erk 1/2 (extracellular signal-regulated kinase 1/2) signal-
ing in skin (23). In keratinocytes, EGF-EGFR-mediated plako-
globin phosphorylation has been shown to decrease the associ-
ation of desmoplakin with the desmosome, thereby reducing
cell-cell adhesion (21, 24). EGFR has been shown to regulate
dsg2 endocytosis in a squamous cell carcinoma cell line. EGFR
promoted dsg2 depletion from themembrane (25). Conversely,
EGFR inhibition increased membrane levels of dsg2 (26) and
cell adhesion in an oral squamous cell carcinoma cell line (27).
Collectively, these studies predict that EGFR inhibition in nor-
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mal human keratinocytes might similarly stabilize desmosome
assembly and cell-cell adhesion. whereas EGFR activation
might promote desmosome disassembly and reduce cell-cell
adhesion.
Pemphigus IgG-inducedEGFRactivationhas been suggested
to contribute to acantholysis by induction of apoptosis. EGFR
inhibition blocked the observed induction of apoptosis by PV
IgG in the immortalized HaCaT keratinocyte line and A431
squamous cell carcinoma cultures (28). However, time course
studies in normal human keratinocyte cultures and inmice sug-
gest that apoptosis is not required for blistering (11, 29). Addi-
tionally, more recent studies did not detect EGFR activation in
pemphigus IgG-treated keratinocyte cultures (30). Another
group observed EGFR activation in keratinocytes treated with
pemphigus IgG (8). However, their studies suggest that p38
activation occurs downstream of, and at time points subse-
quent to, EGFR activation. The EGFR inhibitor erlotinib has
been used to block blistering in the passive transfer mouse
model. However, the authors of this study interpreted their
results to implicate a role for apoptosis in the mechanism of
acantholysis (31).
Because of the role of EGFR in dsg trafficking and the seem-
ingly conflicting reports on the role of EGFR in pemphigus
acantholysis, we explored the potential for EGFR to contribute
to themechanismbywhich pemphigus IgG induce loss of adhe-
sion in keratinocytes. In this study we not only attempt to fur-
ther elucidate the mechanism of PV IgG-induced acantholysis
but to clarify the involvement of EGFR in this cascade.We show
that the basal activity of the EGFR contributes to desmosome
stability; that EGFR is activated by PV IgG; that EGFR activa-
tion is upstream of PV IgG-induced keratin intermediate fil-
ament retraction and dsg3 endocytosis and downstream of
PV IgG-induced p38 activation; and that EGFR inhibitors
block PV IgG-mediated keratin intermediate filament
retraction, dsg internalization, and blistering in vivo using
the passive transfer mouse model of pemphigus. Collec-
tively, these observations identify EGFR as a potential target
for pemphigus disease management.
EXPERIMENTAL PROCEDURES
Materials—Rabbit polyclonal anti-dsg3 antibodies were
fromSerotec (Oxford, UK).Mousemonoclonal E-cadherin and
cytokeratin AE5/8 antibodies were from BD Biosciences. Phos-
pho-EGFR (pY845) antibodies and human recombinant EGF
were from Invitrogen. EEA1, total EGFR receptor antibodies,
and rabbit polyclonal phospho-ERK antibodies were from Cell
Signaling Technology, Inc. (Danvers, MA). Rabbit polyclonal
ERK-1 and ERK-2 antibodies were from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). Mouse and rabbit anti-sheep
horseradish peroxidase-conjugated secondary antibodies were
from GE Healthcare. Fluorescent secondary antibodies were
from Jackson ImmunoResearch Laboratories, Inc. (West
Grove, PA). The p38 inhibitor SB202190 and the EGFR inhibi-
tors AG1478; CL387,785; PD15330; BPIQ-II; erlotinib; and
gefitinib were fromCalbiochem (La Jolla, CA). Normal primary
human keratinocytes, Epilife keratinocyte growth medium,
human keratinocyte growth supplement, and antibiotics were
from Invitrogen.
IgG Preparation—AK 23 antibodies were generated in
hybridoma cells as described previously (32). PV IgG was pre-
pared from the serum of a single patient with confirmedmuco-
cutaneous PV (indirect immunofluorescence titer 1:640). Both
PV IgG and AK23 were prepared by ammonium sulfate precip-
itation followed by affinity chromatography on protein G
(HiTrap, Pharmacia, Piscataway, NJ) as described previously
(12). IgG fractions were dialyzed against PBS and sterile-fil-
tered. Purity was confirmed by SDS-PAGE, and activity was
assayed by indirect immunofluorescence and ELISA. NH IgG
(no activity by indirect immunofluorescence) was prepared in
parallel from normal human sera.
Tissue Culture—Normal primary human keratinocytes were
passaged and expanded as described (12). Third-passage kera-
tinocytes were grown to 80–90% confluence. Keratinocyte
mediumwas supplemented with CaCl2 to a final concentration
of 0.5 mM 3 h prior to treating cells. For some experiments,
keratinocytes were preincubated with the p38 inhibitor
SB202190 or the EGFR inhibitors AG1478; CL387,785;
PD15330; BPIQ-II; erlotinib; gefitinib; or DMSO vehicle con-
trol at 37 °C as described in the figure legends. Cells were then
treated with PBS, NH IgG (2 mg/ml), PV IgG (2 mg/ml), or
AK23 (2 mg/ml) for the indicated times and harvested.
Confocal Microscopy—Confocal microscopy was performed
as described previously (11–13). Keratinocytes were grown on
glass coverslips to 90% confluence, treated, fixed in 3.7% para-
formaldehyde at 4 °C for 10 min, and then washed three times
in 2% BSA in PBS for 10 min. Cells were then permeabilized
using 0.5% Triton X-100 for 10 min at 4 °C followed by three
5-min washes using 2% BSA in PBS. After blocking the cells in
5% goat serum in PBS for 1 h at room temperature, cells were
probed with primary antibodies overnight at 4 °C as described
in the figure legends. The followingmorning, cells were washed
using 2% BSA in PBS for three 10-min washes. Cells were then
incubated with fluorescent secondary antibodies at room tem-
perature for 1 h as described in the figure legends. Coverslips
weremounted on glass slides, and images were analyzed using a
Leica SP2 AOBS confocal microscope using excitation wave-
lengths of 488, 512, and 561 nm. Images were viewed using a
63 objective with a numerical aperture of 1.4 at 2 magnifi-
cation. Double- and triple-labeled samples were checked for
bleed-through by turning off the various lasers and assaying for
the absence of an image. Independent representative images
were assembled using Adobe Photoshop. Brightness and con-
trast were adjusted uniformly.
shRNA Transfection—Primary keratinocytes were grown to
60–80% confluence and transfected with shGFP (as control
shRNA) or with shRNA against EGFR (clone identification
TRCN0000121204, ThermoScientific, Rockford, IL) in me-
dium containing 10 M polybrene and incubated at 37 °C
according to the recommendations of the manufacturer. After
4–6 h, the medium was aspirated, and fresh cell culture
medium was added, incubated for an additional 3 days, and
then utilized for experiments.
Cell Surface Biotinylation—Following treatment, keratino-
cyte cell surface proteins were labeled using EZ Link Sulfo NHS
SS biotin (Pierce) at a concentration of 1 mg/ml at 4 °C on a
rocking platform. After 1 h, the biotin was quenched using 500
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mM ammonium chloride, and cells were lysed in buffer A (50
mM NaCl, 10 mM PIPES, 3 mM MgCl2, 1% Triton X-100) using
probe sonication. Lysates were clarified by centrifugation at
14,000 rpm for 10min at 4 °C. Clarified lysateswere passed over
NeutraAvidin-agarose beads (Pierce) and incubated at room
temperature for 1 h in an end-over-end mixer. Following three
washeswith bufferA, cell surface proteinswere eluted using 1
Laemmli buffer with 50 mM DTT. Western blot analysis was
performed using anti-dsg3 and anti-E-cadherin antibodies.
Preparation of Detergent-soluble and Detergent-insoluble
Fractions—Monolayer cells grown to confluence were ex-
tracted in cell lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50
mMTris-HCl (pH 7.4), 1mMEDTA, 10ME64, 100M leupep-
tin, 10 M pepstatin, and 1 mM phenylmethylsulfonyl fluoride)
at 4 °C for 1 h with rotating and then centrifuged at 13,700  g
for 15 min at 4 °C. The supernatants were collected as deter-
gent-soluble fractions. The pellets werewashed twicewith PBS,
resuspended by incubation in urea lysis buffer (8 M urea, 4%
CHAPS, 10 mM Tris-HCl (pH 7.4)) for 1 h at 4 °C, and then
centrifuged as above. The supernatant was used as the deter-
gent-insoluble fraction. Samples were loaded equally on and
separated by SDS-PAGE. Immunoblotting was performed
according to established protocols and developed by ECL reac-
tion (Amersham Biosciences).
Dispase Assay—Keratinocytes were grown in 12-well plates
until confluent. Cells were washed, andmedium containing 0.5
mM CaCl2 was added to the cells with or without 10 M
AG1478. Two hours later, 2 mg/ml PV IgG was added to the
appropriate wells. Alternatively, cells were treated with 100
ng/ml EGF. After 24 h, cells were washed and incubated in
dispase II (2 units/ml, Roche) for 30min at 37 °C. To subject the
cell sheet to shear force, the floating cell sheet was pipetted up
and down three times with a 1-ml pipette. The fragments were
counted under the light microscope at 2.5 magnification.
Passive Transfer Mouse Model—Breeding pairs of C57BL-6J
mice were purchased from The Jackson Laboratory (Bar Har-
bor, ME) and maintained at the University of North Carolina
Division of Laboratory AnimalMedicine Facility in accordance
with International Animal Care and Use Committee protocols.
Neonatal mice (24- to 36-h-old with body weights between 1.4
and 1.6 g) were used for passive transfer experiments. Neonates
were injected intradermallywith a sterile solutionof either control
IgG or PV IgG as described (9–11). For in vivo inhibitor studies,
mice were pretreated with 4 g of AG1478 in 50 l intradermally
2 h prior to injectionwith PV IgG. After clinical examination, ani-
malsweresacrificed, andskinspecimenswereobtained for routine
histological examination (hematoxylin and eosin staining) using
light microscopy and direct IF assays to detect keratinocyte cell
surface-bound human IgG. No increased mortality was observed
in the inhibitor versus control mice. Statistical significance was
determined using the non-parametric chi square test.
RESULTS AND DISCUSSION
Pemphigus Autoantibody-induced Activation of the EGFR Is
p38-dependent—To investigate the role of the EGFR in pem-
phigus, primary human keratinocytes were grown to conflu-
ency and treated for 30 min with either control NH IgG or PV
IgG. EGFwas used as a positive control for EGFR activation. PV
IgG stimulated EGFR phosphorylation (1.8  0.6-fold com-
pared with the control, n  4, p  0.031), although not to the
extent of EGF (Fig. 1, A–C). One of the mediators of EGFR
signaling is ERK,whose phosphorylation occurs downstreamof
EGFR activation. Thus, we next investigated whether PV IgG
induced ERK phosphorylation. Consistent with the activation
of EGFR by PV IgG, PV IgG induced phosphorylation of ERK
(Fig. 1D), and PV IgG-induced ERKphosphorylationwas inhib-
ited with the EGFR inhibitor AG1478. Activated EGFRs are
rapidly endocytosed (33).Weutilized this property of the EGFR
as a third assay for EGFR activation (Fig. 1E). Keratinocytes
were grown to confluency and treated for 4 h with either con-
trol NH IgG or PV IgG. Confocal immunofluorescent staining
using EGFR-specific antibodies demonstrated PV IgG-induced
endocytosis of the EGFR. EGF-stimulated EGFR endocytosis
was used as a positive control.
Activation of EGFR can be p38-dependent. For example, in
several human cell lines, including colon carcinoma cells, pan-
creatic carcinoma cells, and HeLa cells, the EGFR has been
shown to be activated in a p38-dependent manner (34–36). In
keratinocytes, disruption of lipid rafts by cholesterol depletion
stimulated EGFR phosphorylation and internalization, which
was also p38-dependent (37). Because of the demonstrated role
for p38 activation in pemphigus, we next investigated the rela-
tionship between PV IgG-triggered EGFR activation and p38
using the p38 inhibitor SB202190 and the EGFR inhibitor
AG1478. PV IgG-induced phosphorylation of the small heat
shock protein (HSP) 27 is p38-dependent (12). As expected,
inhibition of p38 blocked PV IgG-induced HSP27 phosphory-
lation (Fig. 1A). Significantly, p38 inhibition blocked PV IgG-
induced EGFR phosphorylation (Fig. 1A), PV IgG-induced
EGFR endocytosis (E), and PV IgG-induced ERK phosphoryla-
tion (D). Although the EGFR inhibitor AG1478 blocked PV
IgG-induced ERK phosphorylation, it did not inhibit PV IgG-
induced p38 phosphorylation, consistent with p38 being
upstream of EGFR and ERK (Fig. 1D). These observations indi-
cate that PV IgG-mediated EGFR phosphorylation and inter-
nalization occur downstream of and are dependent on p38
activity. Interestingly, p38 inhibition failed to block EGF-in-
duced EGFR endocytosis (Fig. 1E), indicating different mecha-
nisms by which PV IgG and EGF induce EGFR endocytosis.
Consistent with the ordering of p38 upstream of EGFR activa-
tion, the EGFR inhibitor AG1478 blocked PV IgG-induced
EGFR phosphorylation but not p38 phosphorylation (Fig. 1B).
It has been suggested that pemphigus patient serum may also
contain non-dsg-targeted autoantibodies that activate “non-
desmoglein” signaling (8). To confirm that EGFR activationwas
a consequence of autoantibody binding to dsg3, we utilized the
pathogenic monoclonal antibody AK23, which binds specifi-
cally within the EC1 extracellular domain of dsg3. Similar to PV
IgG, AK23 stimulated EGFR internalization, and AK23-stimu-
lated EGFR internalization was blocked with the p38 inhibitor
SB202190, confirming that EGFR activation directly follows
autoantibody binding to dsg3 (Fig. 1E).
EGFR Inhibition Blocks Pemphigus Autoantibody-triggered
Keratin Intermediate Filament Retraction and Desmoglein
Internalization—Following pemphigus autoantibody binding
to dsg3, the keratin intermediate filament network retracts
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from the cellmembrane. Significantly, p38 inhibition blocks PV
IgG-induced keratin intermediate filament retraction (11–13).
We next examined the relationship between PV IgG-induced
EGFR activation and keratin intermediate filament retraction
utilizing the EGFR inhibitor AG1478 (Fig. 2). Consistent with
results published previously, PV IgG causes the marked redis-
tribution and retraction of keratin in keratinocytes pretreated
with vehicle control, whereas p38 inhibition prevented PV IgG-
induced keratin retraction. Significantly, EGFR inhibition also
blocked PV IgG-induced keratin retraction.
PV IgG stimulates the internalization of dsg3 into endo-
somes and its subsequent degradation (13, 38–41). PV IgG-
induced keratin intermediate filament retraction and dsg3
endocytosis may be mechanistically linked events that lead to
the loss of cell-cell adhesion (13). Confocal immunofluores-
cence and cellular fractionation studies were utilized to inves-
tigate the relationship of EGFR to dsg3 endocytosis. In PBS- or
NH IgG-treated keratinocytes, dsg3 is localized primarily at the
plasma membrane (Fig. 3A). Consistent with previous studies,
both PV IgG and AK23 caused the internalization of dsg3
within 4 h. Pretreating keratinocytes with the EGFR inhibitor
AG1478 blocked the ability of both PV IgG and AK23 to stim-
ulate the endocytosis of dsg3.
PV IgG-induced depletion of dsg3 from the cell surface likely
contributes to the loss of cell adhesion seen in pemphigus.
Because EGFR inhibition blocked PV IgG-mediated dsg3 endo-
cytosis, we examined the relationship of EGFR inhibition to the
depletion of dsg3 from the membrane. Consistent with reports
published previously, pemphigus autoantibodies caused the
depletion of dsg3 from both the detergent-soluble and deter-
gent-insoluble pools (Fig. 3B). In agreement with the above
immunofluorescence studies, EGFR inhibition similarly
blocked pemphigus autoantibody-triggered loss of dsg3 from
both the detergent-soluble and detergent-insoluble cell frac-
tions (Fig. 3B). To further substantiate the finding that inhibit-
ing EGFR impairs PV IgG-mediated dsg3 depletion, we down-
regulated the EGFR using shRNA. Similar to the use of EGFR
inhibitors, shRNA knockdown of the EGFR reduces the effect
of PV IgG on dsg3 depletion (Fig. 3C).
To confirm the effect of EGFR inhibition on PV IgG-medi-
ated dsg3 depletion, we tested additional EGFR inhibitors,
including those approved for use in patients. As seen in the
confocal images of Fig. 4A, the EGFR inhibitors AG1478;
CL387,785; PD15330; BPIQ-II; erlotinib; and gefitinib prevent
PV IgG-induced dsg3 redistribution from themembrane to the
cytosol. When analyzed by immunoblot, the EGFR inhibitors
similarly blocked PV IgG-inducedmembrane depletion of dsg3
(Fig. 4, B and C).
Inhibiting Basal EGFR Activity Stabilizes Desmosome Adhe-
sion—Inhibition of basal EGFR activity has been demonstrated
to increase cell adhesion in an oral squamous cell carcinoma
cell line (27), suggesting a potential for basal EGFR activity to
contribute to desmosomal adhesion in primary keratinocytes.
Therefore, we next investigated the potential for inhibition of
FIGURE 1. p38 is upstream of EGFR activation by PV IgG. A and B, immunoblot analysis of keratinocyte lysates probed with antibodies to phospho-EGFR
(pEGFR), total EGFR (EGFR), phospho-HSP27 (pHSP27), total HSP27 (HSP27), phospho-p38 (pp38), and total p38 (p38). Unlike NH IgG, PV IgG stimulated EGFR,
p38, and HSP27 phosphorylation. The p38 inhibitor SB202190 blocked PV IgG-induced phosphorylation of EGFR (A) as well as HSP27, previously identified to
be downstream of PV IgG-induced p38 activity. In contrast, the EGFR inhibitor AG1478 blocked PV IgG-induced EGFR phosphorylation but not PV IgG-induced
p38 phosphorylation (B), indicating that p38 acts upstream of EGFR in PV IgG-treated keratinocytes. C, quantitation of PV IgG-stimulated EGFR phosphorylation
in the presence and absence of SB202190 and AG1478. PV IgG stimulated EGFR phosphorylation 1.8  0.6-fold compared with the control (Con). *, p  0.031.
Primary human keratinocytes were grown to confluence, serum-starved overnight, preincubated for 3 h with 0.5 mM calcium and for 1 h in vehicle (dimethyl
sulfoxide), the EGFR inhibitor AG1478 (10 M) (A), or the p38 inhibitor SB202190 (10 M) (B) and then treated with NH IgG or PV IgG for 30 min or EGF (100 ng/ml,
positive control) for 5 min. Cell lysates were prepared, and immunoblot analysis was performed. In addition to EGFR, each blot was also probed for HSP27 (A)
or p38 (B) as loading controls. Results shown are representative of three independent experiments. D, PV IgG induced ERK phosphorylation. Keratinocyte
monolayers were treated with normal human control IgG (Con IgG, 2 mg/ml) or PV IgG (2 mg/ml) for 30 min. Alternatively, keratinocytes were pretreated for 1 h
with either SB202190 (10 M) or AG1478 (10 M) and then treated with PV IgG for 30 min. Lysates were prepared, separated by SDS-PAGE, and probed by
immunoblot analysis with antibodies to phosphorylated p38 (phospho-p38), total p38 (p38), phosphorylated ERK (phospho-ERK), and ERK1 and ERK2.
E, confocal immunofluorescent images of EGFR-stained keratinocytes. Keratinocytes were grown as above on coverslips; treated with PBS, EGF (100 ng/ml), NH
IgG (2 mg/ml), PV IgG (2 mg/ml), or AK23 (2 mg/ml) for 4 h, and then fixed and stained with Cy-2 (1:100)-conjugated anti-EGFR secondary antibodies. In contrast
to buffer (PBS)- and NH IgG-treated controls, EGF, PV IgG and AK23 induced EGFR endocytosis. SB202190 blocked both PV IgG- and AK23-induced EGFR
endocytosis but not EGF-triggered EGFR endocytosis. Results shown are representative of at least three independent experiments.
EGFR in Pemphigus
9450 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288 • NUMBER 13 • MARCH 29, 2013
basal EGFR activity to increase desmosome adhesion and con-
tribute to the mechanism by which EGFR inhibitors make des-
mosomes more resistant to PV IgG-mediated disruption.
Because EGFR inhibition prevented PV IgG-induced loss of cell
surface dsg3, we next tested whether EGFR inhibition altered
the amount of membrane-associated dsg3 under basal condi-
tions. A dose-dependent increase in cell membrane-associated
dsg3 was observed when primary human keratinocytes were
incubatedwith the EGFR inhibitor AG1478 (Fig. 4D). Similarly,
two additional EGFR inhibitors, gefitinib and erlotinib, also
increased the amount of cell membrane-associated dsg3 in a
dose-dependent manner (Fig. 4E). To link the increase of dsg3
protein to enhanced desmosome formation and stability, we
also looked at plakoglobin expression, an essential component
of the desmosomal cadherin complex in AG1478-treated cells.
As shown in Fig. 4D, plakoglobin protein levels also increase
with escalating concentrations of AG1478. The functional
consequence of up-regulated dsg3 and plakoglobin levels
should be stronger cell-cell adhesion. Therefore, we next
utilized the dispase assay to investigate the ability of EGFR
inhibitors to functionally stabilize cell adhesion. Consistent
with the hypothesis that EGFR inhibitors stabilize cell-cell
adhesion, cells treated with AG1478 displayed fewer frag-
ments than control cells. Furthermore, pretreatment with
AG1478 significantly decreased the number of fragments
induced by PV IgG (Fig. 4F).
The specificity of the effect of EGFR inhibition for dsg3 was
demonstrated in confocal immunofluorescence studies, show-
ing that PV IgG caused EGFR-dependent dsg3 endocytosis but
had no effect on the localization of the adherens junction adhe-
sion protein E-cadherin (Fig. 5A). As an additional means to
examine this effect, we next employed cell surface biotinylation
studies. Consistent with the above immunofluorescence
results, the EGFR inhibitor AG1478 partially blocked the PV
IgG-induced loss of dsg3 from the cell surface (Fig. 5B). In con-
trast to PV IgG, no effect on dsg3 depletion was observed when
keratinocytes were incubated with EGF (Fig. 6A), indicating
that dsg3 depletion is downstream of PV IgG-mediated EGFR
signaling but not downstream of EGF-mediated EGFR activa-
tion. Furthermore, EGF did not induce loss of cell-cell adhesion
because no additional fragmentation was observed in the dis-
pase assay when keratinocyte monolayers were incubated with
EGF relative to control monolayers (Fig. 6B).
PV IgG Causes the Colocalization of EGFR, dsg3, and Plako-
globin into Endosomes—In this study, both EGFRanddsg3were
shown separately to be internalized following PV IgG treat-
ment. Using confocal immunofluorescent microscopy, we then
determined whether EGFR and dsg3 colocalized into endo-
somes in PV IgG-treated keratinocytes (Fig. 7). ControlNH IgG
FIGURE 2. The EGFR inhibitor blocks PV IgG-induced keratin intermediate
filament retraction. Confocal immunofluorescent images of keratinocytes
treated with NH or PV IgG  the p38 inhibitor SB202190 or the EGFR inhibitor
AG1478. Primary human keratinocytes were grown as described above; pre-
treated for 1 h with either vehicle (dimethyl sulfoxide), SB202190 (10 M), or
AG1478 (10 M) as indicated; and then treated with NH IgG or PV IgG for 4 h.
To study the effects on dsg3 and cytokeratin, Cy2-conjugated (1:100) and
Cy3-conjugated (1:75) secondary antibodies were used to stain for PV IgG/
Dsg3 (green) and keratin 5 (red), respectively. As expected, when compared
with NH IgG (top panel), PV IgG caused dsg3 endocytosis and keratin interme-
diate filament retraction. In contrast, both SB202190 and AG1478 blocked PV
IgG-induced dsg3 endocytosis and keratin retraction, indicating that both
p38 and EGFR activation occur upstream of these acantholysis-related events.
FIGURE 3. The EGFR inhibitor AG1478 blocks PV IgG- and AK23-triggered
dsg3 internalization. A, no dsg3 endocytosis was observed in PBS or NH IgG
controls. Both PV IgG- and AK23-stimulated internalization was blocked by
AG1478. Keratinocytes were preincubated with AG1478 or vehicle (as
described in Fig. 2) and treated with PBS, NH IgG, PV IgG, or AK23, as indicated,
for 4 h. B, the EGFR inhibitor AG1478 antagonized PV IgG-induced dsg3 deple-
tion from the detergent-soluble and detergent-insoluble cell fractions. Pri-
mary human keratinocytes were grown as described above; preincubated
with either vehicle control (dimethyl sulfoxide) or AG1478 (10 M); and then
treated with PBS, NH IgG, or PV IgG. After 18 h, detergent-soluble and deter-
gent-insoluble lysates were prepared, and Western blot analysis was per-
formed. In detergent-soluble fractions, PV IgG treatment caused a marked
depletion of dsg3 that was blocked by AG1478. Similarly, PV IgG-induced
dsg3 depletion from the detergent-insoluble fraction was blocked by
AG1478. C, down-regulating the EGFR prevents dsg3 depletion by PV IgG.
Primary keratinocytes were transfected with shRNA against GFP or EGFR.
After 3 days, cells were treated with PBS, NH IgG, or PV IgG. After 4 h, cell
lysates were prepared, and Western blot analysis was performed with anti-
bodies to dsg3, EGFR, or lactate dehydrogenase V (LDH-V) as a loading con-
trol. Results shown are representative of three independent experiments.
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failed to induce internalization of either dsg3 or EGFR, whereas
EGF treatment caused the internalization and colocalization of
EGFRwith the early endosomemarker EEA1but did not induce
dsg3 internalization. In contrast, in PV IgG-treated keratino-
cytes, both EGFR and dsg3 partially colocalized with EEA1,
indicating that EGFR and dsg3 colocalize into early endosomes.
It has been proposed that EGFR can phosphorylate plakoglo-
bin, leading to the destabilization of desmosomes (24). Addi-
tionally, pemphigus autoantibody treatment of keratinocytes
has been shown to induce the colocalization of plakoglobin and
EGFR (41). Therefore, we next investigated the dependence of
plakoglobin-EGFR colocalization on EGFR activity. Keratino-
cytes were treated with NH IgG, PV IgG, or PV IgG and the
EGFR inhibitor AG1478, and the distribution of bound PV IgG
(to detect dsg3), plakoglobin, EGFR, and EEA1 was examined
by confocal immunofluorescent microscopy (Fig. 8). After
treatment with PV IgG, but not control NH IgG, colocalization
of plakoglobin, EGFR, and PV IgG (dsg3) was detected in inter-
nal vesicular structures that stained with the early endosome
marker EEA1. PV IgG-induced plakoglobin internalization was
blocked in cells treated with the EGFR inhibitor AG1478, indi-
cating that this internalization event was EGFR-dependent.
The EGFR Inhibitor AG1478 Prevents Blistering in the PV
Passive Transfer Mouse Model—The observation that EGFR
inhibition blocked PV IgG-induced dsg3 internalization and
depletion, plakoglobin internalization, keratin intermediate fil-
ament retraction, and loss of cell-cell adhesion suggested a
mechanistic role for EGFR activation in pemphigus-induced
FIGURE 4. EGFR inhibitors block dsg3 depletion. A, keratinocytes grown on coverslips were serum-starved overnight and preincubated with 0.5 mM calcium
and vehicle  10 M AG1478; CL387,785; PD15330; BPIQ-II; erlotinib; or gefitinib; treated as indicated for 4 h; and then fixed and stained with Cy-2-conjugated
(1:100) secondary antibodies against dsg3 in NH IgG-treated cells or Cy-2-conjugated anti-human IgG for PV IgG-treated cells. In contrast to NH IgG-treated
controls, PV IgG caused the endocytosis of dsg3. EGFR inhibitors blocked PV IgG-induced dsg3 internalization. B and C, EGFR inhibitors blocked PV IgG-induced
dsg3 depletion. Keratinocytes were grown and preincubated with 0.5 mM calcium and the EGFR inhibitor as indicated. NH IgG or PV IgG were added 2 h later.
After 18 h, cell lysates were prepared and subjected to immunoblot analysis with antibodies to dsg3 and GAPDH (loading control). D and E, EGFR inhibitors
increase basal dsg3 levels. Keratinocytes were cultured as above and incubated in the presence of AG1478, gefitinib, or erlotinib at the indicated concentra-
tions for 18 h. Immunoblot analysis of cell lysates with antibodies to dsg3, plakoglobin (PG), and GAPDH show increased levels of dsg3 and PG with EGFR
inhibition. F, EGFR inhibition stabilizes cell-cell adhesion and antagonizes the acantholytic effects of PV IgG in vitro. Cells were grown to confluence and
pretreated with 0.5 mM calcium and 10 M AG1478. Two hours later, 2 mg/ml PVIgG was added. 24 h later, a dispase assay was performed. Data are expressed
as the number of fragments/well  S.D. n  3. *, p  0.05.
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acantholysis. We next tested the contribution of EGFR activity
to blistering in vivo utilizing the PV IgG passive transfer mouse
model. Neonatalmicewere treatedwithNH IgG, PV IgG, or PV
IgG and the EGFR inhibitor AG1478 (n  3 per treatment
group) (Fig. 9A). The EGFR inhibitor prevented PV IgG-in-
duced epidermal blistering. PV IgG bound to keratinocyte cell
surfaceswas detected in skin biopsies fromPV IgG aswell as PV
IgG  inhibitor-treated mice, indicating that the EGFR inhibi-
tor was functioning downstream of PV IgG binding to kerati-
nocyte cell surface dsg3 (Fig. 9B).
DISCUSSION
In keratinocytes treated with PV IgG or the pathogenic anti-
dsg3 monoclonal antibody AK23, we observed EGFR phos-
phorylation and endocytosis. The dependence of these events
on EGFR activity was evidenced by the ability of pharmacologic
EGFR inhibition to block PV IgG-induced endocytosis of dsg3
and plakoglobin, keratin intermediate filament retraction, and
PV IgG-induced loss of keratinocyte cell-cell adhesion both in
vitro and in vivo. Additionally, shRNA knockdown of the EGFR
similarly prevented PV IgG-induced endocytosis of dsg3.
PV IgG-mediated activation of the EGFR was dependent on
p38 activity because pharmacologic inhibition of p38 with
SB202190 blocked PV IgG-induced phosphorylation and endo-
cytosis of the EGFR. In contrast to PV IgG, no effect on dsg3
depletion or cell-cell adhesion was observed when keratino-
cytes were incubated with EGF, providing additional support
FIGURE 5. The effect of PV IgG and EGFR inhibition is dsg3-specific. PV
IgG-induced cell surface depletion of dsg3 was blocked by the EGFR inhibitor
AG1478. In contrast, PV IgG did not induce E-cadherin depletion. A, keratino-
cytes were treated with NH IgG, PV IgG, or PV IgG and the EGFR inhibitor
AG1478 and then examined by confocal immunofluorescent microscopy. PV
IgG stimulated the endocytosis of dsg3 (Cy2, 1:100) but not E-cadherin (Cy3,
1:75). PV IgG-stimulated dsg3 endocytosis was blocked with AG1478. B, cell
surface biotinylation studies. Keratinocytes were treated with NH IgG or PV
IgG  AG1478 and labeled with a membrane-impermeable biotin cell surface
label. Biotin-labeled proteins were purified from lysates on NeutraAvidin-
agarose beads and subjected to immunoblot analysis with antibodies to dsg3
or E-cadherin.
FIGURE 6. In contrast to PV IgG, EGF does not induce dsg3 depletion or
loss of cell-cell adhesion. A, keratinocyte monolayers were treated with NH
IgG (2 mg/ml), PV IgG (2 mg/ml), or EGF (100 ng/ml) for the indicated times.
Lysates were prepared and probed by immunoblot analysis with antibodies
to dsg3. B, no additional cell fragments were observed by the dispase assay in
EGF-treated versus control keratinocyte monolayers. Cells were grown to con-
fluence and incubated for 24 h in the presence (EGF) or absence (Control) of
100 ng/ml EGF, after which the dispase assay was performed. The data are
expressed as number of fragments/well  S.D. (n  6).
FIGURE 7. EGFR and dsg3 colocalize in early endosomes following PV IgG
treatment. Confocal images of control NH IgG, EGF, and PV IgG-treated kera-
tinocytes labeled with antibody specific for dsg3 (green), EGFR (red), and the
early endosome marker EEA1 (blue). Primary human keratinocytes were
treated for 4 h with NH IgG, EGF, or PV IgG and probed for PV IgG (dsg3-Cy2,
1:100), EGFR (Cy3, 1:75), and EEA1 (Cy5, 1:50). In NH IgG-treated cells, both
dsg3 and EGFR remained at the cell surface and did not colocalize with EEA1.
In EGF-treated cells, EGFR, but not dsg3, was internalized. EGFR and EEA1
appeared to partially colocalize in early endosomes. In PV IgG-treated cells,
dsg3 and EGFR undergo endocytosis and partially colocalize with EEA1 in
early endosomes.
FIGURE 8. Plakoglobin colocalizes with dsg3 and EGFR in early endo-
somes following PV IgG treatment. Primary human keratinocytes were
treated for 4 h with NH IgG, PV IgG, or PV IgG and the EGFR inhibitor AG1478
and probed for PV IgG (dsg3-Cy2, 1:100), plakoglobin (Cy3, 1:75), and EEA1
(Cy5, 1:50). In PV IgG-treated cells, dsg3 and plakoglobin partially colocalized
in early endosomes (A). In addition, following PV IgG treatment, dsg3, EGFR,
and plakoglobin also partially colocalized (B). Conventional (A) and orthogo-
nal (B) views are shown.
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for mechanistically distinguishing activation of EGFR by PV
IgG versus EGF. EGFR inhibitors did not block PV IgG-medi-
ated phosphorylation of p38 and HSP27. However, p38 inhibi-
tors blocked EGFR activation as well as phosphorylation of
ERK, a downstreammediator of EGFR signaling. This suggests
that for PV IgG-induced signaling, p38 activation is upstreamof
EGFR activation. Furthermore, inhibition of basal EGFR activ-
ity in primary keratinocytes resulted in increased levels of
membrane-associated dsg3 and plakoglobin as well as in-
creased cell-cell adhesion. Thus, in addition to activation of
EGFR by PV IgG, our data also support a contribution of basal
EGFR activity to desmosome adhesion in primary human kera-
tinocytes. Collectively, these observations support a mechanis-
tic role for EGFR in the cellular events leading to acantholysis in
pemphigus.
Previous studies examining the potential role of EGFR in
pemphigus have produced mixed results. For example, in a
prior study it was suggested that EGFR might function to
potentiate the proapoptotic effect of PV IgG (28). However,
apoptosis does not appear to be required for pemphigus-in-
duced blistering. Results from our laboratory have confirmed
that althoughmarkers of apoptosis are elevated following pem-
phigus autoantibody treatment of keratinocytes, apoptosis
occurs as a secondary event that may have the ability to sensi-
tize cells to, but is not required for, pemphigus IgG-mediated
acantholysis (11), an observation confirmed by other investiga-
tors (29). A second report suggested that although EGFR is
activated, it is done so independently of autoantibody binding
to dsg3, a process referred to as “desmoglein-independent sig-
naling” (8). To study whether EGFR activation was a result of
desmoglein-independent signaling, we used the pathogenic
anti-dsg3 monoclonal antibody AK23 (42). Internalized dsg3 is
targeted for degradation, which leads to its depletion and likely
contributes to the loss of cell adhesion. Similar to PV IgG, we
found that AK23 induced the endocytosis of both dsg3 and
EGFR and that EGFR inhibitors blocked AK23-stimulated dsg3
endocytosis. Because AK23 is a monoclonal antibody-specific
for dsg3, we interpret these results to indicate that the activa-
tion of EGFR following PV IgG treatment is due to autoanti-
body binding to dsg3 and subsequent downstream signaling
events.
A third report proposed that pemphigus pathogenesis is
independent of EGFR (30). In this third report, positive signals
from antibody-based detection systems such as Western blot-
ting, ELISA, and immunofluorescence were suggested to result
from cross-reactivity with secondary antibodies to high
amounts of human pemphigus autoantibody. Our results from
this study indicate that nonspecific cross-reactivity in our
experimental system is an unlikely explanation for our ability to
detect EGFR activation by PV IgG. For example, the increased
signal we see on Western blot analysis from phospho-EGFR
antibodies is sensitive to AG1478. If cross-reactivity were the
reason for an increased signal, the signal should remain high
regardless of the application of EGFR inhibitors. Additionally,
we demonstrate that these specific EGFR inhibitors block sev-
eral in vitro events associated with acantholysis, including PV
IgG-induced dsg3 membrane depletion, dsg3 endocytosis, ker-
atin intermediate filament retraction, and loss of cell-cell adhe-
sion, as well as blistering in mice. Prior studies have shown that
EGFR could directly phosphorylate plakoglobin in A431 squa-
mous cell carcinoma keratinocytes, which destabilized desmo-
somes (24). Following PV IgG binding, dsg3 is internalized in a
clathrin- and dynamin-independentmechanism (40, 41). Inter-
estingly, the pan-tyrosine kinase inhibitor genistein was also
able to block PV IgG-triggered dsg3 internalization (40), per-
haps in part because of EGFR inhibition. We suggest that the
detection by immunoblot of the transient, relative to EGF
ligand, weak phosphorylation of EGFR is suboptimal and that
this may in part explain the conflicting data in the literature on
the role of EGFR in pemphigus. Despite this limitation, two
additional assays of EGFR activation, EGFR endocytosis and
phosphorylation of the downstream signaling mediator ERK,
similarly support the activation of EGFR by PV IgG. Further-
more, the inhibition of EGFR, whether by pharmacologic inhi-
bition or genetic knockdown, gave consistent results inhibiting
PV IgG mediated dsg3 endocytosis.
Our results are consistent with these prior studies. p38 is
activated in diverse cell processes, including cell stress re-
sponses, apoptosis, proliferation, and receptor endocytosis
(43). We have previously shown p38 to be activated following
PV IgG binding to dsg3 (12). Inhibiting p38 blocks PV IgG-
induced keratin intermediate filament retraction, actin reorga-
nization, and dsg3 endocytosis in primary keratinocytes. Fur-
thermore, p38 inhibition blocked blistering in both PV and PF
passive transfermousemodels (9, 10). There are several reports
in the literature suggesting that p38 can modulate EGFR activ-
ity and internalization. Cells subjected to cytotoxic stress such
as UV irradiation and chemotherapeutic agents activate p38
which, in turn, was shown to be responsible for EGFR phos-
phorylation and internalization (44). Unlike EGF-induced
FIGURE 9. The EGFR inhibitor AG1478 blocks blister formation in vivo.
Neonatal mice were preinjected with either vehicle or AG1478 for 2 h and
then treated by intradermal injection with either NH IgG or PV IgG (n  3 per
treatment group). After 18 h, the mice were sacrificed, and skin from the
injection site was harvested and stained by H&E (A) or examined by direct
immunofluorescence using anti-human IgG to detect bound PV IgG (B). PV
IgG-treated but not NH IgG-treated mice demonstrated characteristic
suprabasilar acantholysis. PV IgG-induced blistering was blocked in mice pre-
treated with AG1478. Mice were examined for the presence of human anti-
dsg3 PV IgG by direct immunofluorescence using a mouse anti-human Cy-2-
conjugated monoclonal antibody. A honeycomb pattern of staining in the
epidermis is seen in both PV IgG-treated and PV IgG  AG1478-treated mice,
demonstrating that the EGFR inhibitor does not prevent binding of PV
autoantibodies to the keratinocyte cell surface. No bound human IgG was
detected in skin biopsies of NH IgG-treated mice. The statistical significance
between the PV IgG-treated and PV IgGAG1478-treated groups was deter-
mined using the chi square test. p  0.014.
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EGFR internalization, p38-dependent EGFR internalization did
not lead to receptor degradation in lysosomes but rather to its
accumulation in early endosomes. Vergarajauregui and col-
leagues (14) demonstrated that activation of p38 by anisomycin
leads to ligand-independent internalization of EGFR. Interest-
ingly, they further show that EGF and anisomycin-induced
p38-dependent EGFR internalization differ in the way the
receptor is trafficked intracellularly. Another report demon-
strates, in keratinocytes, that following disruption of detergent-
resistant lipid rafts, both p38 and EGFR are activated and that
p38 is upstream of EGFR (37). Our results also indicate that in
the PV IgG signal transduction cascade, p38 is activated
upstream of EGFR because p38 inhibition also inhibited PV
IgG-induced EGFR activation as measured by EGFR phos-
phorylation, EGFR internalization, and ERK phosphorylation.
We interpret the data to indicate that these events contribute to
the subsequent loss of dsg3 from desmosomes and, in turn, to
keratinocyte acantholysis. As such, this study suggests a thera-
peutic role for EGFR inhibitors in pemphigus and provides a
biologic rationale for pursuing clinical trials of EGFR inhibitors
in PV.
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